A $325 million settlement has been reached in the Neurontin class action lawsuit involving third-party payors, who claimed Pfizer delayed generic versions of the drug. This follows a previous $190 million settlement. The agreement aims to reimburse payors for higher costs due to Pfizer's alleged anticompetitive practices.